Growth Metrics

Ironwood Pharmaceuticals (IRWD) Other Non-Current Liabilities (2016 - 2026)

Ironwood Pharmaceuticals' Other Non-Current Liabilities history spans 14 years, with the latest figure at $21.6 million for Q4 2025.

  • On a quarterly basis, Other Non-Current Liabilities rose 26.56% to $21.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $21.6 million, a 26.56% increase, with the full-year FY2025 number at $21.6 million, up 26.56% from a year prior.
  • Other Non-Current Liabilities hit $21.6 million in Q4 2025 for Ironwood Pharmaceuticals, down from $22.2 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for IRWD hit a ceiling of $39.8 million in Q3 2024 and a floor of $1.5 million in Q2 2021.
  • Historically, Other Non-Current Liabilities has averaged $17.3 million across 5 years, with a median of $17.2 million in 2024.
  • Biggest five-year swings in Other Non-Current Liabilities: soared 478.86% in 2022 and later tumbled 44.14% in 2025.
  • Tracing IRWD's Other Non-Current Liabilities over 5 years: stood at $3.5 million in 2021, then skyrocketed by 178.95% to $9.8 million in 2022, then surged by 190.96% to $28.4 million in 2023, then crashed by 39.8% to $17.1 million in 2024, then rose by 26.56% to $21.6 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for IRWD at $21.6 million in Q4 2025, $22.2 million in Q3 2025, and $22.5 million in Q2 2025.